Latest Australian Manufacturing News

Pharmaceutical manufacturer ANO has been hit with a US FDA Import Alert, joining several Australian peers amid wider regulatory tensions. The company is mobilising expert consultants and preparing a petition to lift the alert within weeks.

Maas Group's JLE subsidiary has landed a $200 million deal to deliver modular electrical infrastructure for a 100MW AI factory cluster in Tasmania, marking a major step into the AI infrastructure sector.

Firebird Metals has secured a key patent for its energy-efficient kiln and announced plans for an Australian Demonstration Plant to commercialise its battery materials technology.

PPK Group reports record revenue at Craig International Ballistics and advances lithium sulfur battery technology, while preparing for a CEO transition and focusing on sovereign manufacturing.

First Graphene has locked in a 12-month exclusive global license to develop and sell graphene-enhanced carbon paste, a breakthrough material already boosting solar cell efficiency and cutting costs.

Saferoads Holdings has divested its Road Safety Rentals business for $10.8 million, repaid debt, and is now focusing on rebuilding its core product sales with new hires and product innovation.

Firebrick Pharma is set to expand its Nasodine product line with the launch of a new throat spray, targeting export markets starting November 2025, beginning with Singapore.

thl reported a tough FY25 with a 45% drop in underlying profit and a statutory loss, but is charting a strategic turnaround while rejecting a $2.30 per share acquisition offer.

International Graphite Limited has taken significant steps toward establishing Australia’s first commercial graphite micronising plant with land acquisition and key development approvals in Collie, WA.

Mayfield Group Holdings has landed a pivotal $20 million contract for the Brigalow Gas Peaking Plant in Queensland, pushing its FY26 contract awards to $37 million and reinforcing its role in Australia's energy transition.

Orica Limited reports robust earnings growth across all segments for FY2025, underpinned by successful gas supply deals, digital expansion, and progress in hydrogen funding despite ongoing litigation costs.

Mayne Pharma reported a 5% revenue increase to $408.1 million for FY25 but posted a net loss of $93.8 million, narrowing from the prior year. The company’s planned acquisition by Cosette Pharmaceuticals faces legal hurdles, delaying completion.